Why the study?
Does abciximab reduce the incidence of post-PCI coronary events in Japanese patients undergoing balloon angioplasty?
Does abciximab reduce the incidence of post-PCI coronary events in Japanese patients undergoing balloon angioplasty?
Abciximab did not demonstrate efficacy in preventing post-PCI coronary events compared to placebo in Japanese patients undergoing balloon angioplasty.
Abciximab shows no reduction in post-PCI coronary events in Japanese balloon angioplasty patients; challenges routine use and extends null findings to this population.
No significant difference in the incidence of coronary events was found between the placebo and abciximab groups, so the efficacy of abciximab in preventing post-PCI coronary events in Japanese patients was not confirmed.
No takes yet. Share an insight, caveat, or question.
Nakagawa et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: